Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYCETIN versus CHLOROPTIC S O P.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYCETIN versus CHLOROPTIC S O P.
CHLOROMYCETIN vs CHLOROPTIC S.O.P.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
50-100 mg/kg/day IV divided every 6 hours; maximum 4 g/day. Topical: apply to affected area 2-4 times daily.
Apply 0.5-inch ribbon into the conjunctival sac(s) 1-2 times daily, or more frequently as directed.
None Documented
None Documented
1.5-4 hours in adults; prolonged to 3-7 hours in neonates and 4-12 hours in hepatic impairment; clinical context: dose adjustment required in liver disease.
Terminal half-life approximately 4-6 hours; clinical context: dosing every 4-6 hours for ocular infections
Renal: 5-10% unchanged; hepatic glucuronidation (90%) followed by renal elimination of metabolites; small biliary excretion (<5%) and fecal elimination.
Renal (70-80% as unchanged drug and metabolites), biliary/fecal (20-30%)
Category C
Category C
Antibiotic
Antibiotic